Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR-2: Salanersen After Onasemnogene Abeparvovec in Infants With SMA
NCT07444450Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Oct 2026
- Primary completion
- Jul 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 3 trial of salanersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started Oct 2026; status: recruiting.
02
Drugs
salanersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT07444450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444450.